These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9327395)

  • 1. Antiviral ribozymes. New jobs for ancient molecules.
    Menke A; Hobom G
    Mol Biotechnol; 1997 Aug; 8(1):17-33. PubMed ID: 9327395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.
    Xing Z; Mahadeviah S; Whitton JL
    Antisense Res Dev; 1995; 5(3):203-12. PubMed ID: 8785476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR.
    Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of the in vitro antiviral activity of an engineered M1GS ribozyme that targets to the core gene of hepatitis C virus].
    Zhang W; Li X; Luo G; Huang Z; Liu Y
    Wei Sheng Wu Xue Bao; 2013 Aug; 53(8):875-81. PubMed ID: 24341280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of viral replication by ribozyme: mutational analysis of the site and mechanism of antiviral activity.
    Zhang Z; Burke JM
    J Virol; 2005 Mar; 79(6):3728-36. PubMed ID: 15731266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of gene expression with ribozymes.
    Marschall P; Thomson JB; Eckstein F
    Cell Mol Neurobiol; 1994 Oct; 14(5):523-38. PubMed ID: 7621511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribozymes: a new frontier in anti-HIV strategy.
    Sarver N
    Antisense Res Dev; 1991; 1(4):373-8. PubMed ID: 1821659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA enzymes (ribozymes) as antiviral therapeutic agents.
    Rossi JJ; Sarver N
    Trends Biotechnol; 1990 Jul; 8(7):179-83. PubMed ID: 1366622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.
    Rossi JJ; Elkins D; Zaia JA; Sullivan S
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):183-9. PubMed ID: 1540406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozymes: the characteristics and properties of catalytic RNAs.
    Tanner NK
    FEMS Microbiol Rev; 1999 Jun; 23(3):257-75. PubMed ID: 10371033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating a new generation of ribozymes in order to target HCV.
    Lévesque MV; Lévesque D; Brière FP; Perreault JP
    PLoS One; 2010 Mar; 5(3):e9627. PubMed ID: 20224783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes.
    Feng Y; Kong YY; Wang Y; Qi GR
    J Gastroenterol Hepatol; 2001 Oct; 16(10):1125-30. PubMed ID: 11686839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus.
    Ohkawa J; Yuyama N; Takebe Y; Nishikawa S; Taira K
    Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11302-6. PubMed ID: 8248243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding.
    Trang P; Hsu A; Zhou T; Lee J; Kilani AF; Nepomuceno E; Liu F
    J Mol Biol; 2002 Jan; 315(4):573-86. PubMed ID: 11812131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-mediated cleavage of an HIV-1 gag RNA: the effects of nontargeted sequences and secondary structure on ribozyme cleavage activity.
    Taylor NR; Rossi JJ
    Antisense Res Dev; 1991; 1(2):173-86. PubMed ID: 1726777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.